The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting
Kaufman H, Atkins M, Dicker A, Jim H, Garrison L, Herbst R, McGivney W, Silverstein S, Wigginton J, Yu P. The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. Journal For ImmunoTherapy Of Cancer 2017, 5: 38. PMCID: PMC5394621, DOI: 10.1186/s40425-017-0241-6.Peer-Reviewed Original ResearchImmunotherapy of cancerCancer immunotherapyThird-party payersBroad clinical activityDurable response rateImmune-based agentsCurrent therapeutic strategiesVariety of malignanciesDistinct side effectsPatient advocacy groupsTraditional cytotoxicsTreatment of cancerConventional therapyPredictive biomarkersClinical activityImmunotherapyClinical OncologyTherapeutic strategiesHealthcare costsSide effectsResponse rateCancerTherapyNational HarborAmerican Society